Advanced Drug Delivery Reviews

Editorial Board
pp. ii-ii(1)

Preface
pp. 1357-1357(1)

An overview of the pathogenesis of cystic fibrosis lung disease
pp. 1359-1371(13)
Author: Boucher R.C.

Barriers to and new approaches for gene therapy and gene delivery in cystic fibrosis
pp. 1373-1393(21)
Authors: Ferrari S.; Geddes D.M.; Alton E.W.F.W.

Therapeutic approaches to repair defects in F508 CFTR folding and cellular targeting
pp. 1395-1408(14)
Authors: Powell K.; Zeitlin P.L.

Pharmacological approaches for the discovery and development of new anti-inflammatory agents for the treatment of cystic fibrosis
pp. 1409-1423(15)
Authors: Konstan M.W.; Davis P.B.

Anaerobic metabolism and quorum sensing by Pseudomonas aeruginosa biofilms in chronically infected cystic fibrosis airways: rethinking antibiotic treatment strategies and drug targets
pp. 1425-1443(19)
Authors: Hassett D.J.; Cuppoletti J.; Trapnell B.; Lymar S.V.; Rowe J.J.; Sun Yoon S.; Hilliard G.M.; Parvatiyar K.; Kamani M.C.; Wozniak D.J.; Hwang S.H.; McDermott T.R.; Ochsner U.A.

Altering airway surface liquid volume: inhalation therapy with amiloride and hyperosmotic agents
pp. 1445-1462(18)
Author: Hirsh A.J.

Inhaled P2Y₂ receptor agonists as a treatment for patients with Cystic Fibrosis lung disease
pp. 1463-1474(12)
Authors: Kellerman D.; Evans R.; Mathews D.; Shaffer C.

Pharmacological approaches to discovery and development of new mucolytic agents
pp. 1475-1490(16)
Authors: King M.; Rubin B.K.

Pharmaceutical and biotechnological aerosols for cystic fibrosis therapy
pp. 1491-1504(14)
Authors: Garcia-Contreras L.; Hickey A.J.

The cystic fibrosis therapeutics development network (CF TDN): a paradigm of a clinical trials network for genetic and orphan diseases
pp. 1505-1528(24)
Authors: Goss C.H.; Mayer-Hamblett N.; Kronmal R.A.; Ramsey B.W.